Abstract
Tmunity Therapeutics, a biotech firm cofounded by cellular therapy pioneer Carl June, has raised $100 million in its first formal round of financing. Ping An Ventures, Gilead Sciences, and the Parker Institute for Cancer Immunotherapy are among the investors in Tmunity, which was launched in 2016 by June and other University of Pennsylvania researchers. Led by Usman Azam, former head of Novartisâs cell and gene therapies unit, the firm is working on T-cell immunotherapies for cancer. The funding is one of several recent large series A rounds. Earlier this month, Gossamer Bio and BioNTech raised $100 million and $270 million, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
